abstract |
FIELD: medicine. n SUBSTANCE: invention relates to a method for the treatment of a condition that is mediated by cystic fibrosis transmembrane conductivity regulator (hereinafter – CFTR) in a patient, including injection to a patient of a Compound (I) represented by the following structural formula: n , or its pharmaceutically acceptable salt in the amount from 150 mg to 200 mg once a day, as well as to a pharmaceutical composition intended for the treatment of a condition mediated by CFTR in a patient, including a pharmaceutically acceptable carrier or diluent and from 150 mg to 200 mg of a compound represented by the following structural formula: n , or its pharmaceutically acceptable salt. n EFFECT: obtaining compounds for the treatment of a condition mediated by CFTR. n 15 cl, 4 tbl, 7 ex, 12 dwg |